dc.contributor.author | Karavasilis, V. | en |
dc.contributor.author | Malamou-Mitsi, Vassiliki D. | en |
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Tsanou, E. | en |
dc.contributor.author | Kitsou, E. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Fotsis, T. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Karavasilis, V. | en |
dc.creator | Malamou-Mitsi, Vassiliki D. | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Tsanou, E. | en |
dc.creator | Kitsou, E. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Fotsis, T. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:44Z | |
dc.date.available | 2018-06-22T09:53:44Z | |
dc.date.issued | 2005 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41997 | |
dc.description.abstract | BACKGROUND. The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP). METHODS. Paraffin-embedded tumor material from 75 patients diagnosed with CUP was used. Tumor histologies were adenocarcinoma (77%), undifferentiated carcinoma (19%), and squamous cell carcinoma (4%) and patients were categorized into favorable (62%) and unfavorable (38%) subsets. The tissue expression of MMP-2, MMP-9, and TIMP-1 was assessed by use of specific monoclonal antibodies and evaluated by means of a visual staining score. The expression of molecules studied was analyzed against clinicopathological data. RESULTS. MMP-2 was found expressed in 69% (strong expression in 49%), MMP-9 in 49% (strong in 36%), and TIMP-1 in 79% (strong in 44%) of studied cases. The expression of MMP-2 correlated positively with MMP-9. TIMP-1 was significantly higher in unfavorable compared with favorable tumors and was associated with a shorter survival of patients (7.5 vs. 12 mos). No other associations were detected. CONCLUSIONS. MMP-2, MMP-9, and TIMP-1 are widely expressed in CUP, suggesting an essential role of proteolysis in these tumors. TIMP-1 may be considered a possible marker of poor prognosis in CUP patients. © 2005 American Cancer Society. | en |
dc.language.iso | eng | en |
dc.source | Cancer | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | 80 and over | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Priority journal | en |
dc.subject | Human tissue | en |
dc.subject | Prognosis | en |
dc.subject | Male | en |
dc.subject | Protein expression | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Monoclonal antibody | en |
dc.subject | Gelatinase a | en |
dc.subject | Gelatinase b | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Squamous cell carcinoma | en |
dc.subject | Biological | en |
dc.subject | Tumor markers | en |
dc.subject | Unknown primary | en |
dc.subject | Carcinoma | en |
dc.subject | Undifferentiated carcinoma | en |
dc.subject | Tumor marker | en |
dc.subject | Human cell | en |
dc.subject | Paraffin | en |
dc.subject | Tissue inhibitor of metalloproteinase 1 | en |
dc.subject | Carcinoma of unknown primary | en |
dc.subject | Carcinoma of unknown-primary | en |
dc.subject | Matrix metalloproteinase | en |
dc.subject | Matrix metalloproteinases | en |
dc.subject | Mmp-2 | en |
dc.subject | Mmp-9 | en |
dc.subject | Protein degradation | en |
dc.subject | Proteolysis | en |
dc.subject | Timp-1 | en |
dc.subject | Tissue inhibitor of metalloproteinases | en |
dc.title | Matrix metalloproteinases in carcinoma of unknown primary | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1002/cncr.21454 | |
dc.description.volume | 104 | |
dc.description.issue | 10 | |
dc.description.startingpage | 2282 | |
dc.description.endingpage | 2287 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Karavasilis, V. [0000-0002-5806-9399] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-5806-9399 | |
dc.gnosis.orcid | 0000-0002-3286-778X | |